LON:AGY - Allergy Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 12.50 0.00 (0.00 %) (As of 05/21/2019 04:00 PM ET)Previous CloseGBX 12.50Today's RangeGBX 12 - GBX 12.5552-Week RangeGBX 8 - GBX 29Volume81,733 shsAverage Volume167,682 shsMarket Capitalization£79.52 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops clinical pipeline products that include vaccines for grass, tree, and house dust mite, as well as a peanut allergy vaccine that is in pre-clinical stage. The company primarily sells its products in European countries. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom. Receive AGY News and Ratings via Email Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:AGY Previous Symbol CUSIPN/A CIKN/A Webhttp://www.allergytherapeutics.com/ Phone+44-1903-844700Debt Debt-to-Equity Ratio6.20 Current Ratio3.74 Quick Ratio3.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£72.82 million Price / Sales1.09 Cash FlowGBX 5 per share Price / Cash Flow2.50 Book ValueGBX 7 per share Price / Book1.79Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees500 Outstanding Shares636,169,024Market Cap£79.52 million Next Earnings DateN/A OptionableNot Optionable Allergy Therapeutics (LON:AGY) Frequently Asked Questions What is Allergy Therapeutics' stock symbol? Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY." What price target have analysts set for AGY? 1 Wall Street analysts have issued 1 year price targets for Allergy Therapeutics' stock. Their predictions range from GBX 35 to GBX 40. On average, they expect Allergy Therapeutics' share price to reach GBX 37.50 in the next year. This suggests a possible upside of 200.0% from the stock's current price. View Analyst Price Targets for Allergy Therapeutics. What is the consensus analysts' recommendation for Allergy Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergy Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergy Therapeutics. Has Allergy Therapeutics been receiving favorable news coverage? News headlines about AGY stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergy Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Allergy Therapeutics' key competitors? Some companies that are related to Allergy Therapeutics include Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Vita Life Sciences (VLS), Futura Medical (FUM), Cathay International (CTI), Patrys (PAB), Recce Pharmaceuticals (RCE), Avivagen (VIV), Antisense Therapeutics (ANP), NanoViricides (NNVC), Sareum (SAR) and China Pharma (CPHI). What other stocks do shareholders of Allergy Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include Relypsa (RLYP), Repros Therapeutics (RPRX), Merrimack Pharmaceuticals (MACK), Spectrum Pharmaceuticals (SPPI), Verastem (VSTM), Berkeley Energia (BKY), Dechra Pharmaceuticals (DPH), Flowtech Fluidpower (FLO), Shanta Gold (SHG) and Sosandar (SOS). Who are Allergy Therapeutics' key executives? Allergy Therapeutics' management team includes the folowing people: Mr. Manuel Llobet, CEO & Exec. Director (Age 55)Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)Ms. Beverly Lees, Group Operations DirectorDr. Murray Skinner, Chief Scientific OfficerMr. Santiago Puig, Bus. Devel. Director How do I buy shares of Allergy Therapeutics? Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Allergy Therapeutics' stock price today? One share of AGY stock can currently be purchased for approximately GBX 12.50. How big of a company is Allergy Therapeutics? Allergy Therapeutics has a market capitalization of £79.52 million and generates £72.82 million in revenue each year. Allergy Therapeutics employs 500 workers across the globe. What is Allergy Therapeutics' official website? The official website for Allergy Therapeutics is http://www.allergytherapeutics.com/. How can I contact Allergy Therapeutics? Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700. MarketBeat Community Rating for Allergy Therapeutics (LON AGY)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 317 (Vote Outperform)Underperform Votes: 163 (Vote Underperform)Total Votes: 480MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: What is a stock buyback? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.